Less intensive surveillance after radical surgery for stage I-III colorectal cancer by focusing on the doubling time of recurrence.
Colorectal carcinoma
Doubling time
Recurrence
Surveillance
Tumor growth rate
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
23
05
2020
accepted:
29
07
2020
pubmed:
17
9
2020
medline:
16
9
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
To propose a new and improved surveillance schedule for colorectal cancer (CRC) patients by focusing on the recurrence rate, resectability, and especially, the tumor doubling time (DT) of recurrent tumors. The subjects of this retrospective review were 1774 consecutive patients who underwent radical surgery for stage I-III CRC between January, 2004 and December, 2015. We calculated the DT by measuring the tumor diameter using computed tomography (CT). The median DT for recurrences in the liver, lung, peritoneum, and other locations were 35, 72, 85, and 36 days, respectively, (p < 0.001) and tumor growth rates differed according to the organs where recurrence developed. Multiple linear regression analysis showed that the DT was strongly associated with the relapse-free interval from primary surgery (p < 0.001), and that the DT in patients with recurrence detected ≥ 3 years after primary surgery was longer by 151.1 days than that in patients with recurrence detected within 1 year after primary surgery. We proposed a less intensive surveillance, which achieved an average cost reduction of 32.5% compared with conventional surveillance in Japan. We propose a new and more cost-efficient surveillance schedule for CRC surgery patients in the clinical setting.
Identifiants
pubmed: 32935208
doi: 10.1007/s00595-020-02135-y
pii: 10.1007/s00595-020-02135-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-560Subventions
Organisme : Japan Society for the Promotion of Science
ID : 17K10620
Organisme : Japan Society for the Promotion of Science
ID : 17K10621
Organisme : Japan Society for the Promotion of Science
ID : 17K10623
Organisme : Japan Society for the Promotion of Science
ID : 18K07194
Organisme : Japan Society for the Promotion of Science
ID : 19K09114
Organisme : Japan Society for the Promotion of Science
ID : 19K09115
Organisme : Japan Agency for Medical Research and Development
ID : JP19cm0106502
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492 .
doi: 10.3322/caac.21492
Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T, et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology. 2003;50:1362–6.
pubmed: 14571738
Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25. https://doi.org/10.1097/01.sla.0000128305.90650.71 .
doi: 10.1097/01.sla.0000128305.90650.71
pubmed: 15166961
pmcid: 1356290
Ike H, Shimada H, Ohki S, Togo S, Yamaguchi S, Ichikawa Y. Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum. 2002;45:468–73. https://doi.org/10.1007/s10350-004-6222-0 .
doi: 10.1007/s10350-004-6222-0
pubmed: 12006927
Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006;202:468–75. https://doi.org/10.1016/j.jamcollsurg.2005.11.008 .
doi: 10.1016/j.jamcollsurg.2005.11.008
pubmed: 16500252
Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2002;1:002200. https://doi.org/10.1002/14651858.CD002200 .
doi: 10.1002/14651858.CD002200
Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26. https://doi.org/10.1186/1471-2407-3-26 .
doi: 10.1186/1471-2407-3-26
pubmed: 14529575
pmcid: 270033
Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99. https://doi.org/10.1007/s10350-007-9030-5 .
doi: 10.1007/s10350-007-9030-5
pubmed: 17874269
Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813. https://doi.org/10.1136/bmj.324.7341.813 .
doi: 10.1136/bmj.324.7341.813
pubmed: 11934773
pmcid: 100789
Wille-Jorgensen P, Syk I, Smedh K, Laurberg S, Nielsen DT, Petersen SH, et al. Effect of more vs. less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage ii or iii colorectal cancer: the COLOFOL randomized clinical trial. JAMA. 2018;319:2095–103. https://doi.org/10.1001/jama.2018.5623 .
doi: 10.1001/jama.2018.5623
pubmed: 29800179
pmcid: 6583244
Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;11:002200. https://doi.org/10.1002/14651858.CD002200.pub3 .
doi: 10.1002/14651858.CD002200.pub3
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263–70. https://doi.org/10.1001/jama.2013.285718 .
doi: 10.1001/jama.2013.285718
pubmed: 24430319
Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, et al. A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. Health Technol Assess. 2017;21:1–86. https://doi.org/10.3310/hta21320 .
doi: 10.3310/hta21320
pubmed: 28641703
pmcid: 5494506
Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274–80. https://doi.org/10.1093/annonc/mdv541 .
doi: 10.1093/annonc/mdv541
pubmed: 26578734
Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34. https://doi.org/10.1007/s10147-017-1101-6 .
doi: 10.1007/s10147-017-1101-6
pubmed: 28349281
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-colon cancer, version 2. 2019. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf . Accessed 13 Dec 2019.
Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015;58:713–25. https://doi.org/10.1097/DCR.0000000000000410 .
doi: 10.1097/DCR.0000000000000410
pubmed: 26163950
Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72. https://doi.org/10.1093/annonc/mdt354 .
doi: 10.1093/annonc/mdt354
pubmed: 24078664
Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic Impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25:1646–53. https://doi.org/10.1245/s10434-018-6436-3 .
doi: 10.1245/s10434-018-6436-3
pubmed: 29572704
Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med. 1956;76:988–1000.
pubmed: 13362715
Collins VP. Time of occurrence of pulmonary metastasis from carcinoma of colon and rectum. Cancer. 1962;15:387–95.
doi: 10.1002/1097-0142(196203/04)15:2<387::AID-CNCR2820150222>3.0.CO;2-5
Miyake H, Murono K, Nagata H, Nozawa H, Kawai K, Hata K, et al. Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer. Int J Colorectal Dis. 2019;34:801–9. https://doi.org/10.1007/s00384-019-03259-5 .
doi: 10.1007/s00384-019-03259-5
pubmed: 30739186
Tanaka K, Shimada H, Miura M, Fujii Y, Yamaguchi S, Endo I, et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg. 2004;28:263–70. https://doi.org/10.1007/s00268-003-7088-3 .
doi: 10.1007/s00268-003-7088-3
pubmed: 14961200
Tanaka K, Shimada H, Fujii Y, Endo I, Sekido H, Togo S, et al. Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbecks Arch Surg. 2004;389:371–9. https://doi.org/10.1007/s00423-004-0490-y .
doi: 10.1007/s00423-004-0490-y
pubmed: 15605168
Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336–46. https://doi.org/10.1245/s10434-006-9071-3 .
doi: 10.1245/s10434-006-9071-3
pubmed: 17235718
Kawaguchi K, Uehara K, Nakayama G, Fukui T, Fukumoto K, Nakamura S, et al. Growth rate of chemotherapy-naive lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection. Int J Clin Oncol. 2016;21:329–34. https://doi.org/10.1007/s10147-015-0889-1 .
doi: 10.1007/s10147-015-0889-1
pubmed: 26280748
Tomimaru Y, Noura S, Ohue M, Okami J, Oda K, Higashiyama M, et al. Metastatic tumor doubling time is an independent predictor of intrapulmonary recurrence after pulmonary resection of solitary pulmonary metastasis from colorectal cancer. Dig Surg. 2008;25:220–5. https://doi.org/10.1159/000140693 .
doi: 10.1159/000140693
pubmed: 18577868
Cucchetti A, Russolillo N, Johnson P, Tarchi P, Ferrero A, Cucchi M, et al. Impact of primary cancer features on behaviour of colorectal liver metastases and survival after hepatectomy. BJS Open. 2019;3:186–94. https://doi.org/10.1002/bjs5.100 .
doi: 10.1002/bjs5.100
pubmed: 30957066
Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer. 1999;86:2668–73.
doi: 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.0.CO;2-R
Mohajeri G, Hejab K, Sheikhbahaei S, Mohajeri M, Niknam N, Mohammadi A. Micrometastasis in colorectal cancer: does it affect staging? ANZ J Surg. 2018;88:E237–E241241. https://doi.org/10.1111/ans.13809 .
doi: 10.1111/ans.13809
pubmed: 27766737
Alsaggar M, Yao Q, Cai H, Liu D. Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Meta. 2016;33:115–24. https://doi.org/10.1007/s10585-015-9761-y .
doi: 10.1007/s10585-015-9761-y
Algire GH, Legallais FY, Anderson BF. Vascular reactions of normal and malignant tissues in Vivo. VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas. J Natl Cancer Inst. 1954;14:879–93.
pubmed: 13233832
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6. https://doi.org/10.1056/NEJM197111182852108 .
doi: 10.1056/NEJM197111182852108
pubmed: 4938153
Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–9. https://doi.org/10.1038/35077241 .
doi: 10.1038/35077241
pubmed: 11357145
Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19:6979–94. https://doi.org/10.3748/wjg.v19.i41.6979 .
doi: 10.3748/wjg.v19.i41.6979
pubmed: 24222942
pmcid: 3819534
Tempero MA, Williams CA, Anderson JC. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. J Clin Oncol. 1986;4:1074–8. https://doi.org/10.1200/JCO.1986.4.7.1074 .
doi: 10.1200/JCO.1986.4.7.1074
pubmed: 3522817
Schneider J, Koullouros M, Mackay C, Ramsay G, Parnaby C, Stevenson L. Is Liver ultrasound useful as part of the surveillance strategy following potentially curative colorectal cancer resection? Dig Dis. 2019;37:234–8. https://doi.org/10.1159/000495114 .
doi: 10.1159/000495114
pubmed: 30466102
Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31:19–311. https://doi.org/10.1002/jmri.22010 .
doi: 10.1002/jmri.22010
pubmed: 20027569
Seo SI, Lim SB, Yoon YS, Kim CW, Yu CS, Kim TW, et al. Comparison of recurrence patterns between </=5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108:9–13. https://doi.org/10.1002/jso.23349 .
doi: 10.1002/jso.23349
pubmed: 23754582
Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248:994–1005. https://doi.org/10.1097/SLA.0b013e3181907fd9 .
doi: 10.1097/SLA.0b013e3181907fd9
pubmed: 19092344
Dorr NM, Bartels M, Morgul MH. Current treatment of colorectal liver metastasis as a chronic disease. Anticancer Res. 2020;40:1–7. https://doi.org/10.21873/anticanres.13921 .
doi: 10.21873/anticanres.13921
pubmed: 31892548
Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64. https://doi.org/10.1245/s10434-015-4387-5 .
doi: 10.1245/s10434-015-4387-5
pubmed: 25631064
Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–53. https://doi.org/10.1038/nm0295-149 .
doi: 10.1038/nm0295-149
pubmed: 7585012